Jurajda V, Salaj J, Pospísil Z
Vet Med (Praha). 1984 Dec;29(12):719-28.
The immunity state after vaccination against Marek's disease (MD) was studied in three multiplier flocks of laying fowl (MFL), five multiplier flocks of broiler fowl (MFB), and one commercial layer flock (CLF). The occurrence and average titres of post-vaccination viraemia in the selected sets of chickens from these flocks, examined at the age of three or twenty weeks, were used as the immunity criterion. The development of post-vaccination viraemia, following the administration of the MARVAK vaccine at the doses of 100 and 1000 PFU per bird in the HX-SL and Shaver layer hybrids, was examined under laboratory conditions at the same time. In the group of birds examined in the third week of age and coming from the MFL vaccinated with the recommended MARVAK vaccine (dose (100 PFU per bird), 64.3% of the chicks were viraemic, the average viraemia titre being 12 PFU/10(7) leucocytes. After the administration of a four-fold vaccine dose, 57.1% of the chicks were viraemic, the average titre being 3.2 PFU/10(7) leucocytes. After the administration of a ten-fold dose of MARVAK vaccine, 80% of the chicks were viraemic and the average titre of viraemia was 8 PFU/10(7) leucocytes. In the MFB vaccinated with the recommended dose of the MARVAK vaccine, the percentage of viraemic chickens was 48.3% and the average titre of viraemia was 6.5 PFU/10(7) leucocytes. In the pullets examined at the age of 20 weeks the number of viraemic birds ranged from 20 to 50% and the average viraemia titres were from 3.8 to 13.1 PFU/10(7) leucocytes. In the flock affected by acute MD, no post-vaccination viraemia was found in the clinically diseases pullets. In the chickens of the HX-SL line vaccinated with the recommended MARVAK vaccine dose, viraemia culminated in the third week after vaccination (31.5 PFU/10(7) leucocytes), and after the use of the dose ten times as high as the recommended one the culmination came a week later (47 PFU/10(7) leucocytes). In the Shaver chicks vaccinated with the recommended dose or with the ten-fold dose of the MARVAK vaccine, the post-vaccination viraemia culminated in the fourth week after vaccination (94.9 and 116.8 PFU/10(7) leucocytes). The post-vaccination precipitation antibodies were first detected in the eighth week after vaccination.
在三个蛋种鸡繁殖群（MFL）、五个肉种鸡繁殖群（MFB）和一个商品蛋鸡群（CLF）中研究了接种马立克氏病（MD）疫苗后的免疫状态。以这些鸡群中选定的鸡在3周龄或20周龄时检测到的接种后病毒血症的发生率和平均滴度作为免疫标准。同时在实验室条件下，对HX-SL和海兰蛋鸡杂交种以每只鸡100和1000 PFU的剂量接种MARVAK疫苗后接种后病毒血症的发展情况进行了研究。在3周龄时检测的来自接种推荐剂量MARVAK疫苗（每只鸡100 PFU剂量）的MFL的鸡群中，64.3%的雏鸡出现病毒血症，病毒血症平均滴度为12 PFU/10⁷白细胞。接种四倍疫苗剂量后，57.1%的雏鸡出现病毒血症，平均滴度为3.2 PFU/10⁷白细胞。接种十倍剂量的MARVAK疫苗后，80%的雏鸡出现病毒血症，病毒血症平均滴度为8 PFU/10⁷白细胞。在接种推荐剂量MARVAK疫苗的MFB中，出现病毒血症的鸡的百分比为48.3%，病毒血症平均滴度为6.5 PFU/10⁷白细胞。在20周龄时检测的青年母鸡中，出现病毒血症的鸡的数量在20%至50%之间，病毒血症平均滴度为3.8至13.1 PFU/10⁷白细胞。在受急性MD影响的鸡群中，临床发病的青年母鸡未发现接种后病毒血症。在接种推荐剂量MARVAK疫苗的HX-SL系鸡中，病毒血症在接种后第三周达到高峰（31.5 PFU/10⁷白细胞），使用推荐剂量十倍的剂量后，高峰在一周后出现（47 PFU/10⁷白细胞）。在接种推荐剂量或十倍剂量MARVAK疫苗的海兰雏鸡中，接种后病毒血症在接种后第四周达到高峰（94.9和116.8 PFU/10⁷白细胞）。接种后沉淀抗体在接种后第八周首次检测到。
